MANGALAM
Small CapMangalam Drugs And Organics Limited
Pharma
Mangalam Drugs And Organics Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
One read, four checks
75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.
Weak fundamentals, management trust is a red flag, price trend argues for patience, and recent execution is weak.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
low confidence · 0/0 claims checked
Timing lens: price trend and sector relative strength.
Rolling lens: recent quarterly delivery, not the latest single-result score.
Quarter ended 31 Mar 2026
Bad · 0/100Rev -8% YoY · margin compression · +16% QoQ
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹67 Cr | -8.2% | +15.5% |
| EBITDA | ₹-6 Cr | -160.0% | -200.0% |
| Operating margin | -8.0% | -2200 bps | -500 bps |
| PAT | ₹-13 Cr | NDF | NDF |
| PAT margin | -19.4% | -1940 bps | -216 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Issuer presentation review pending
Mangalam Drugs And Organics Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 31 Mar 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trend score and candlestick chart
44NeutralSMA20 -9.9% / mo · near 52W low
Technical chart
MANGALAMdaily · 3Y-52.8%Technical trend read
NeutralTrend is undirectional — long-term trend unclear. RSI 40.
- SMA20 roughly flat — short-term momentum stalled.
- RSI(14) at 40 — sideways, no extreme reading.
- MACD below signal but histogram contracting — bearish momentum easing.
- 55% off 52W high · 24% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation, score drivers, trust methodology, financials, and peers
Use these sections after reviewing the decision summary, latest result, thesis, management accountability, and technical timing above.
Fundamental score breakdown
OVERVALUEDWhy this score?
Top U-Score contributors and drags from the latest stored fundamentals.
Positive drivers
- Valuation contributes 5/30 to the score.
- Cash flow contributes 1/10 to the score.
- Balance sheet contributes 1/15 to the score.
Main drags
- Altman Z is 1.2, in distress territory.
- Penalty bucket subtracts 7 points.
- Quality is weaker at 0/20; verify the latest quarterly trend.
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Score history
12 stored score snapshots. Latest stored move: +0 points.
Factor attribution
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Low Trust: Claim history is still being built. It ranks around the 1st percentile of the scored universe and 1st percentile within Pharma. Main check: results consistency is weak at 5/100.
Low Trust Lite: Promoter pledge is zero. Key concern: Promoter holding fell 14.7%.
Avoid relying on management narrative unless turnaround evidence is hard and recent.
overall median 67 · Pharma: 1st pctile, median 70 · Small: 1st pctile, median 65
0 documents indexed, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Low Trust · low confidenceRead Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust positives
- ▸Promoter pledge is zero.
Trust risks
- ▸Promoter holding fell 14.7%.
- ▸Altman Z is 1.22.
- ▸4 recent quarters had PAT decline worse than 25% YoY.
- ▸Only 1 years of positive FCF.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Intrinsic value
Fundamentals
Valuation
- P/E
- —
- P/B
- 0.44
- EV/EBITDA
- 50.00
- Market Cap
- 45.00Cr
Profitability
- ROE
- -35.20%
- ROCE
- -14.30%
- ROA
- -13.97%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- -26.00%
- EPS 5Y
- -26.00%
- Revenue 3Y
- -35.00%
- EPS 3Y
- -35.00%
Balance Sheet
- Debt/Equity
- 1.02
- Interest Coverage
- -0.94×
- Altman Z
- 1.21
- Book Value
- 65.10
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 1/5
- OCF
- 4.00 Cr
- EPS TTM
- -28.05
Shareholding
- Promoter Hold
- 35.65%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 8%
Financial History
Updated 9/6/2026
Revenue
₹ CrNet Profit
₹ CrReturn on Equity
%Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.